<DOC>
	<DOCNO>NCT02623426</DOCNO>
	<brief_summary>The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy ( MERIT ) Trial compare relative efficacy safety intravitreal methotrexate , intravitreal ranibizumab , intravitreal dexamethasone implant treatment uveitic macular edema persist intravitreal corticosteroid injection . MERIT parallel design ( 1:1:1 ) , randomize comparative trial anniversary close-out 6 month clinic visit . The primary outcome percent change central subfield thickness baseline OCT measurement 12 week visit .</brief_summary>
	<brief_title>Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial</brief_title>
	<detailed_description>Macular edema ( ME ) common structural complication cause visual impairment legal blindness uveitis patient . Traditional approach treatment uveitic ME include use regional corticosteroid therapy , deliver periocularly , include posterior sub-Tenon 's orbital floor injection , via intravitreal route . While corticosteroid injection may reduce ME improve vision , effect often variable limited duration . Persistent macular edema common occurrence often require repeated intravitreal injection corticosteroid , expose eye significant risk increase intraocular pressure ocular cataract development . The often refractory nature uveitic ME impact visual function underscore need identify effective alternative medical therapeutic option . Recent pilot study show intravitreal methotrexate ( MTX ) intravitreal ranibizumab ( Lucentis® , Genentech Inc. , San Francisco , CA ) promise treatment uveitic ME , intravitreal dexamethasone implant ( Ozurdex® , Allergan , Irvine , CA ) recently approve U.S. FDA uveitic ME patient non-infectious uveitis . In addition effective , intravitreal MTX ranibizumab potentially may less ocular side effect corticosteroid , particularly less IOP elevation . However , relative efficacy treatment unknown . The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy ( MERIT ) Trial compare relative efficacy safety intravitreal methotrexate , ranibizumab , dexamethasone implant . MERIT parallel design ( 1:1:1 ) , randomize comparative effectiveness trial anniversary close-out 6 month clinic visit . The primary outcome percent change central subfield thickness baseline OCT measurement 12 week visit .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Eye level inclusion criterion least one eye must meet following condition : 1 . Inactive minimally active noninfectious anterior , intermediate , posterior panuveitis , define SUN criterion ≤ 0.5+ anterior chamber cell , ≤ 0.5+ vitreous haze grade active retinal/choroidal lesion minimum 4 week ; 2 . Macular edema ( ME ) define presence macular thickness great normal range OCT machine use ( see cut point ) , regardless presence cyst , follow intravitreal corticosteroid injection ( ≥ 4 week follow intravitreal triamcinolone injection ≥ 12 week follow intravitreal dexamethasone implant injection ) ; Greater 300 μm Zeiss Cirrus Greater 320 μm Heidelberg Spectralis Greater 300 μm Topcon 3DOCT 3 . Baseline fluorescein angiogram , assess study ophthalmologist , gradable degree leakage central subfield ; 4 . Best correct visual acuity ( BCVA ) 5/200 good ; 5 . Baseline intraocular pressure &gt; 5 mm Hg ≤ 21 mm Hg ( current use ≤3 intraocular pressurelowering medication and/or prior glaucoma surgery acceptable ) ; 6 . Media clarity pupillary dilation sufficient allow OCT test assessment fundus ; Patient level exclusion criterion 1 . History infectious uveitis either eye ; 2 . History scleritis keratitis type either eye ; 3 . History central serous retinopathy either eye ; 4 . Active infectious conjunctivitis either eye ; 5 . Oral prednisone dose &gt; 10 mg per day ( alternative corticosteroid dose higher equipotent prednisone 10 mg per day ) OR oral prednisone dose ≤ 10 mg per day stable least 4 week ; 6 . Systemic immunosuppressive drug therapy stable least 28 day ( note use systemic methotrexate acceptable long regimen stable least 28 day ) ; 7 . Use oral acetazolamide systemic carbonic anhydrase inhibitor baseline ; 8 . Known allergy hypersensitivity component study drug ; 9 . For woman childbearing potential : pregnancy , breastfeeding , positive pregnancy test ; unwilling practice adequate birth control method ( abstinence , combination barrier spermicide , hormonal ) duration trial ; Eye level exclusion criterion least one eye meet inclusion criterion follow condition 10 . History infectious endophthalmitis ; 11 . History uncontrolled glaucoma define optic nerve damage ( cup/disc ratio ≥ 0.9 notching optic nerve rim ) ; 12 . Presence epiretinal membrane note clinically OCT per judgment study ophthalmologist may significant enough limit improvement ME ( i.e. , cause substantial wrinkle retinal surface ) ; 13 . Torn rupture posterior lens capsule ; 14 . Presence silicone oil ; 15 . Ozurdex administer past 12 week ; 16 . AntiVEGF agent , intravitreal methotrexate , intravitreal/periocular corticosteroid administer past 4 weeksIntravitreal/periocular corticosteroid administer past 4 week ; 17 . Fluocinolone acetonide implant ( Retisert ) place past 3 year ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>uveitic macular edema</keyword>
	<keyword>uveitis</keyword>
</DOC>